OGI
Organigram Global, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$1.05
−1.87%Year over year
Reported trailing growth
- Revenue
- +38.1%
- EBITDA
- +402.1%
- EBIT
- +67.7%
- EPS
- +1961.9%
- Free cash flow
- -75.1%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +6.3%
- EBITDA
- +162.5%
- EPS
- -94.6%
Three-year CAGR
- Revenue
- +8.5%
- EBITDA
- +34.9%
- EBIT
- -82.4%
- Net income
- +60.9%
- EPS
- +70.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026